CancerPhase 3NCT07620574

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

A Phase 3 study testing Cabozantinib, Zanzalintinib and Atezolizumab in people with Cancer and Renal Cell Carcinoma (RCC), run by Exelixis at 2 sites in United States.

Enrolling by invitation

Enrolling by invitation. The study team selects and invites participants, usually from an existing group of patients.

Sites and contacts

Official record

Search all trials

Trial summary

The primary objective of this long-term extension study is to allow continued access to study treatment for eligible participants who are deriving clinical benefit in an Exelixis-sponsored study who do not have access to treatment locally. Read more about this study

Who is it for?: Any age
Conditions the study is for: Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET)
What is being tested?: Cabozantinib, Zanzalintinib and Atezolizumab
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 5,000 participants
Where: 2 sitesUnited States
Study dates: 30 Jul 2026to 31 May 2030
Phase: Phase 3

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages Any age
All sexes
No healthy volunteers
Child, Adult, Older adult

Who may be able to join

Eligible to continue receiving the study treatment in the parent study (that is, has not met parent study discontinuation/withdrawal criteria).
Continuing to derive clinical benefit from the study treatment at the time of transition from the parent study as assessed by the investigator.
Able to comply with the long-term extension study protocol as determined by the investigator.
Able to receive the first dose of study treatment in this extension study within the specified treatment interruption window allowed by the parent study.

Who cannot join

Meet any of the study treatment discontinuation criteria specified in the parent study at the time of enrollment in this extension study.
Study treatment is commercially marketed in the participant's country for the participant-specific disease and is accessible to the participant.
Treatment with any anticancer treatment (other than treatment permitted in the parent study) during the time between last treatment in the parent study and the first dose of study treatment in this long-term extension study.
Permanent discontinuation of all study treatment(s) for any reason during the parent study or during the time between last treatment in the parent study and the first dose of study treatment in this long-term extension study (if applicable).
Concurrent participation in any therapeutic clinical trial (other than the parent study).
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

United States2 sites

New York Cancer and Blood Specialists
Bay Shore, New York, 11706
Greater Dayton Cancer Center
Kettering, Ohio, 45409

Other trials in United States

About this study

Conditions: Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET), Hepatocellular Carcinoma (HCC), Differentiated Thyroid Cancer (DTC)
Being tested: Cabozantinib, Zanzalintinib, Atezolizumab, Nivolumab, Abiraterone
Keywords: Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET), Hepatocellular Carcinoma (HCC), Differentiated Thyroid Cancer (DTC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Colorectal Cancer
Medical subject headings: Neoplasms, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Colorectal Neoplasms, Prostatic Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

CabozantinibDrug
Also called XL184, Cabometyx
Administered as specified in the parent study.
ZanzalintinibDrug
Also called XL092
Administered as specified in the parent study.
AtezolizumabDrug
Administered as specified in the parent study.
NivolumabDrug
Administered as specified in the parent study.
AbirateroneDrug
Administered as specified in the parent study.
PrednisoneDrug
Administered as specified in the parent study.
EnzalutamideDrug
Administered as specified in the parent study.

Study groups in NCT07620574
Study group	Role	What they receive
Cabozantinib/Zanzalintinib	Experimental	Depending on the study treatment received in the parent study, participants may receive cabozantinib alone or in combination with other agents; zanzalintinib alone or in combination with other agents, or comparator. Receives: Drug: Cabozantinib; Drug: Zanzalintinib; Drug: Atezolizumab; Drug: Nivolumab; Drug: Abiraterone; Drug: Prednisone; Drug: Enzalutamide

What is being measured

The primary outcome is the main question the study is designed to answer.

Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Measured: Up to 4 years (until the event resolves, returns to baseline, stabilizes, a new anticancer therapy is initiated, or the participant is lost to follow-up or withdraws consent, whichever occurs first)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

30 Jul 202631 May 2030

First posted2 Jun 2026
Study start30 Jul 2026
Primary completion31 May 2030 (estimated)
Study completion31 May 2030 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for CancerStudies of the same condition, open and under way.
More trials run by ExelixisThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 3
Primary purpose: Treatment
Allocation: Not applicable
Intervention model: Single group
Masking: None (open label)
Enrolment: 5,000 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT07620574
Sponsor's protocol ID: EXEL-LTE-1
Other IDs: 2026-525795-26-00
Status last verified: Aug 2026
First submitted: 27 May 2026
Last updated: 18 Aug 2026
Results posted: No
Data monitoring committee: No
FDA-regulated drug: Yes
FDA-regulated device: No
Individual data sharing: No